Puma Biotechnology Inc (NASDAQ:PBYI) price on Friday, May 02, rose 4.22% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $3.21.
A look at the stock’s price movement, the close in the last trading session was $3.08, moving within a range at $3.07 and $3.25. The beta value (5-Year monthly) was 1.333 while the PE ratio in trailing twelve months stood at 5.26. Turning to its 52-week performance, $5.26 and $2.22 were the 52-week high and 52-week low respectively. Overall, PBYI moved 6.64% over the past month.
Puma Biotechnology Inc’s market cap currently stands at around $159.31 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-26.
Analysts have a consensus estimate of 44.55M for the company’s revenue for the quarter, with a low and high estimate of 44.1M and 45M respectively. The average forecast suggests up to a 1.79% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 218.2M, representing a -5.34% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that PBYI is a 50% Sell. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 1 recommend PBYI as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
PBYI’s current price about 8.59% and 2.61% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 58.87, while 7-day volatility ratio is 4.85% and 5.31% in the 30-day chart. Further, Puma Biotechnology Inc (PBYI) has a beta value of 1.29, and an average true range (ATR) of 0.15.
If we refocus on Puma Biotechnology Inc (NASDAQ:PBYI), historical trading data shows that trading volumes averaged 0.25 over the past 10 days and 367.32K over the past 3 months. The company’s latest data on shares outstanding shows there are 49.11 million shares.
The 21.66% of Puma Biotechnology Inc’s shares are in the hands of company insiders while institutional holders own 53.91% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 2.87 million on 2025-04-15, giving us a short ratio of 8.03. The data shows that as of 2025-04-15 short interest in Puma Biotechnology Inc (PBYI) stood at 680.0000000000001 of shares outstanding, with shares short rising to 2.79 million registered in 2025-03-14. Current price change has pushed the stock 5.25% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the PBYI stock continues to rise going into the next quarter.
